1
|
Mudgal A, Kumar K, Mollereau C, Pasha S. NPYFa, A Chimeric Peptide of Met-Enkephalin, and NPFF Induces Tolerance-Free Analgesia. Chem Biol Drug Des 2016; 87:885-94. [DOI: 10.1111/cbdd.12721] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 11/30/2015] [Accepted: 12/30/2015] [Indexed: 12/11/2022]
Affiliation(s)
- Annu Mudgal
- Peptide Synthesis Laboratory; CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi India
- Academy of Scientific and Innovative Research (AcSIR); CSIR-IGIB Campus; New Delhi India
| | - Krishan Kumar
- Peptide Synthesis Laboratory; CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi India
- Department of Chemistry; Motilal Nehru College; University of Delhi; Delhi 110021 India
| | - Catherine Mollereau
- Institut de Pharmacologie et Biologie Structurale; Toulouse Cedex France
- Laboratoire Anthropologie Moléculaire et Imagerie de Synthèse; Toulouse Cedex France
| | - Santosh Pasha
- Peptide Synthesis Laboratory; CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi India
- Academy of Scientific and Innovative Research (AcSIR); CSIR-IGIB Campus; New Delhi India
| |
Collapse
|
2
|
Csabafi K, Jászberényi M, Bagosi Z, Tóth G, Wollemann M, Telegdy G. The action of a synthetic derivative of Met5-enkephalin-Arg6-Phe7 on behavioral and endocrine responses. Peptides 2011; 32:1656-60. [PMID: 21722680 DOI: 10.1016/j.peptides.2011.05.029] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Revised: 05/24/2011] [Accepted: 05/24/2011] [Indexed: 11/19/2022]
Abstract
The neuroendocrine and behavioral effects of Tyr-D-Ala-Gly-Phe-D-Nle-Arg-Phe (DADN), a more stable derivative of the endogenous opiate Met-enkephalin related peptide Met(5)-enkephalin-Arg(6)-Phe(7) were investigated in mice. The behavioral experiments consisted of monitoring the horizontal (square crossing) and vertical (rearing) locomotion in the open field system. To evaluate the effect of the heptapeptide on the hypothalamo-pituitary-adrenal (HPA) axis, the plasma corticosterone level was measured. DADN induced dose-dependent increases in locomotion and rearing 30 min after intracerebroventricular injection and also elicited marked activation of the hormonal stress response. To elucidate the receptors involved in the mediation of these actions, animals were pretreated with the nonselective opioid antagonist naloxone, the selective κ-receptor antagonist nor-binaltorphimine or the μ(1)-receptor blocker naloxonazine. Both the HPA activation and the behavioral responses were diminished by the preadministration of naloxone. Nor-binaltorphimine did not display a significant effect, while naloxonazine completely abolished the hyperactivity and the corticosterone elevation elicited by the analog. These findings suggest that μ-receptors predominate in the mediation of the neuroendocrine actions of DADN, while κ-receptors do not play a significant role.
Collapse
Affiliation(s)
- Krisztina Csabafi
- Department of Pathophysiology, University of Szeged, Semmelweis u. 1., P.O. Box 427, Szeged H-6701, Hungary
| | | | | | | | | | | |
Collapse
|
3
|
Bojnik E, Boynik E, Corbani M, Babos F, Magyar A, Borsodi A, Benyhe S. Phylogenetic diversity and functional efficacy of the C-terminally expressed heptapeptide unit in the opioid precursor polypeptide proenkephalin A. Neuroscience 2011; 178:56-67. [DOI: 10.1016/j.neuroscience.2011.01.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2010] [Revised: 01/04/2011] [Accepted: 01/05/2011] [Indexed: 01/28/2023]
|
4
|
Vats ID, Chaudhary S, Sharma A, Nath M, Pasha S. Rationally designed chimeric peptide of met-enkephalin and FMRFa-[D-Ala2, p-Cl-Phe4]YFa induce multiple opioid receptors mediated antinociception and up-regulate their expression. Eur J Pharmacol 2010; 638:54-60. [DOI: 10.1016/j.ejphar.2010.02.060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2009] [Revised: 02/02/2010] [Accepted: 02/24/2010] [Indexed: 10/19/2022]
|
5
|
Vats ID, Chaudhary S, Karar J, Nath M, Pasha Q, Pasha S. Endogenous peptide: Met-enkephalin-Arg-Phe, differently regulate expression of opioid receptors on chronic treatment. Neuropeptides 2009; 43:355-62. [PMID: 19716174 DOI: 10.1016/j.npep.2009.07.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Revised: 06/24/2009] [Accepted: 07/26/2009] [Indexed: 11/24/2022]
Abstract
Endogenous peptide, Met-enkephalin-Arg-Phe (Tyr-Gly-Gly-Phe-Met-Arg-Phe; MERF) induces effects like antinociception, inhibit contraction of guinea pig ileum, mouse vas deferens and anti-tussive action. However, results regarding its functional efficiency and selectivity are controversial. Therefore, present study was undertaken to investigate whether MERF on systemic (intra-peritoneal, i.p.) route of administration induce any antinociception or not; to scrutinize the effect of 6 days chronic i.p. treatment of MERF on expression of mu (MOR1), delta (DOR1) and kappa (KOR1) opioid receptors; and finally, the antinociceptive effect of two synthetic peptides, MERFamide and (D-Ala(2))-MERFamide was compared with MERF on intracerebroventricular administration in order to understand the role of FMRF moiety in analgesic effect of MERF. Pharmacological results revealed that only 68.4 and 91.2 micromol/kg dose induce significant antinociception among various doses. Further, on 6 days chronic treatment, MERF induced significant antinociception in comparison to saline. Differential expression of MOR1 and KOR1 showed continuous up-regulation throughout the treatment whereas DOR1 showed down-regulation in initial 3 days followed by subsequently up-regulation during the latter observable period. Moreover, variation in opioid receptors expression had not affected the MERF antinociception. In conclusion, present study discursively demonstrates that MERF during chronic treatment interacts with all three opioid receptors (mu, delta and kappa) in rats and differently regulates their expression. Further, the interaction was such that the induction was mainly observed at molecular/expression level and not at pharmacological level to affect antinociception.
Collapse
Affiliation(s)
- Ishwar Dutt Vats
- Peptide Synthesis Laboratory, Institute of Genomics and Integrative Biology, Delhi, India
| | | | | | | | | | | |
Collapse
|
6
|
Vats ID, Snehlata, Nath M, Pasha MAQ, Pasha S. Effect of chronic intra-peritoneally administered chimeric peptide of met-enkephalin and FMRFa-[D-Ala2]YFa-on antinociception and opioid receptor regulation. Eur J Pain 2009; 14:295.e1-9. [PMID: 19560378 DOI: 10.1016/j.ejpain.2009.05.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Revised: 05/16/2009] [Accepted: 05/23/2009] [Indexed: 11/29/2022]
Abstract
The physiological role of NPFF/FMRFa family of peptides is complex and exact mechanism of action of these peptides is not yet completely understood. In same line of scrutiny, previously we reported an enzymatically stable chimeric analog of YGGFMKKKFMRFamide (YFa) i.e., [D-Ala(2)]YAGFMKKKFMRFamide ([D-Ala(2)]YFa) which have a role in antinociception and modulatory effect on opioid analgesia. In continuation, presently we investigated using tail-flick test whether [D-Ala(2)]YFa on systemic administration induced any antinociception in rats and if so then which specific opioid receptor(s) mu, delta or kappa mediated it. Further, the antinociceptive effect of [D-Ala(2)]YFa on 6 days chronic intra-peritoneal (i.p.) treatment in rats was examined and finally, effect of this chronic treatment on the differential expression of opioid receptors was assessed. [D-Ala(2)]YFa on i.p. administration induced dose dependent antinociception which was mainly mediated by delta (DOR) and partially by mu (MOR) and kappa (KOR) opioid receptors. Moreover, its antinociceptive effect remained comparable throughout the chronic treatment even during insufficient availability of DOR1. Importantly, during this treatment the mRNA expression of all three opioid receptors (MOR1, KOR1 and DOR1) was increased as assessed by real-time RTPCR though subsequent western blot analysis revealed a selective increase in the protein level of DOR1, only. Thus, pharmacological behavior of [d-Ala(2)]YFa suggests that competency of an opioid agonist to bind with multiple opioid receptors may enhance its potency to induce tolerance free analgesia.
Collapse
Affiliation(s)
- Ishwar Dutt Vats
- Peptide Synthesis Laboratory, Institute of Genomics and Integrative Biology, Delhi, India
| | | | | | | | | |
Collapse
|
7
|
Gonzalez-Nuñez V, Toth G, Rodríguez RE. Endogenous heptapeptide Met-enkephalin-Gly-Tyr binds differentially to duplicate delta opioid receptors from zebrafish. Peptides 2007; 28:2340-7. [PMID: 18022288 DOI: 10.1016/j.peptides.2007.10.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2007] [Revised: 10/04/2007] [Accepted: 10/04/2007] [Indexed: 11/28/2022]
Abstract
Met-enkephalin-Gly-Tyr (MEGY) is an endogenous peptide that binds to opioid sites in zebrafish and in rat brain homogenates. The aim of this work is to characterize the binding profile of this opioid ligand on two duplicate delta receptors from zebrafish, ZFOR1 and ZFOR4. Our results show that, while ZFOR1 presents one single binding site for [(3)H]-MEGY (K(D)=4.0+/-0.4 nM), the experimental data from ZFOR4 fit better to the two-site binding model (K(D1)=0.8+/-0.2 nM and K(D2)=30.2+/-10.2 nM). Two other MEGY synthetic analogues, (D-Ala(2))-MEGY and (D-Ala(2), Val(5))-MEGY were also prepared and tested, together with the original peptide MEGY and other opioid ligands, in competition binding assays. While these peptides presented K(i) values on the nanomolar range when using [(3)H]-MEGY as radioligand, these parameters were two orders higher in competition binding assays with the antagonist [(3)H]-diprenorphine. Functional [(35)S]GTPgammaS stimulation analysis has revealed that these two receptors can be activated by several opioid agonists. Our results prove that although the MEGY peptide acts as an agonist on ZFOR1 and ZFOR4, there are subtle pharmacological differences between these two delta opioid receptors from zebrafish.
Collapse
Affiliation(s)
- Veronica Gonzalez-Nuñez
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Salamanca, Spain
| | | | | |
Collapse
|
8
|
Masand G, Hanif K, Sen S, Ahsan A, Maiti S, Pasha S. Synthesis, conformational and pharmacological studies of glycosylated chimeric peptides of Met-enkephalin and FMRFa. Brain Res Bull 2006; 68:329-34. [PMID: 16377439 DOI: 10.1016/j.brainresbull.2005.09.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2005] [Accepted: 09/12/2005] [Indexed: 10/25/2022]
Abstract
Our previous study showed that a chimeric peptide of Met-enkephalin and FMRFamide, YFa (YGGFMKKKFMRFa) not only caused antinociception and potentiated morphine analgesia but also blocked the development of tolerance and physical dependence. In the continuation of that study three chimeric analogues of YFa, [Ser5]YFa, [O-Glu-Ser5]YFa and [O-Gal-Ser5]YFa, were synthesized. To increase the bioavailability and penetration of blood brain barrier (BBB), glycosylated analogues, [O-Glu-Ser5]YFa and [O-Gal-Ser5]YFa, have been synthesized by solid phase peptide synthesis by building block method using anomeric acetate activation method. Circular dichroism studies showed that all the three chimeric peptides are stable and have a propensity for adopting helical conformation in the presence of membrane mimicking solvent. In comparison of parent chimeric peptide YFa, helicity of [Ser5]YFa, [O-Glu-Ser5]YFa and [O-Gal-Ser5]YFa has decreased. Pharmacological studies using tail-flick latency in mice showed that [O-Glu-Ser5]YFa have increased analgesia and bioavailability in comparison of [O-Gal-Ser5]YFa and non-glycosylated analogue [Ser5]YFa. Exhibition of enhanced analgesia by [O-Glu-Ser5]YFa as compared to [O-Gal-Ser5]YFa seems to be due to preference of GLUT-1 transporter system for glucose.
Collapse
Affiliation(s)
- Gita Masand
- Peptide Synthesis Laboratory, Institute of Genomics and Integrative Biology, Mall Road, Delhi 110007, India
| | | | | | | | | | | |
Collapse
|
9
|
González-Nuñez V, Arsequell G, Szemenyei E, Toth G, Valencia G, Rodriguez RE. Binding Profile of the Endogenous Novel Heptapeptide Met-Enkephalin-Gly-Tyr in Zebrafish and Rat Brain. J Pharmacol Exp Ther 2005; 314:862-7. [PMID: 15901806 DOI: 10.1124/jpet.105.084558] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Zebrafish is considered a model organism, not only for the study of the biological functions of vertebrates but also as a tool to analyze the effects of some drugs or toxic agents. Five opioid precursor genes homologous to the mammalian opioid propeptide genes have recently been identified; one of these, the zebrafish proenkephalin, codes a novel heptapeptide, the Met-enkephalin-Gly-Tyr (MEGY). To analyze the pharmacological properties of this novel ligand, we have labeled it with tritium ([(3)H]MEGY). In addition, we have also synthesized two analogs: (d-Ala(2))-MEGY (Y-d-Ala-GFMGY) and (d-Ala(2), Val(5))-MEGY (Y-d-Ala-GFVGY). The binding profile of these three agents has been studied in zebrafish and rat brain membranes. [(3)H]MEGY presents one binding site in zebrafish, as well as in rat brain membranes, although it shows a slight higher affinity in zebrafish brain. The observed saturable binding is displaced by naloxone, thus confirming the opioid nature of the binding sites. Competition binding assays indicate that the methionine residue is essential for high-affinity binding of MEGY and probably of other peptidic agonists in zebrafish, whereas the change of a Gly for a d-Ala does not dramatically affect the ligand affinity. Our results show that the percentage of [(3)H]MEGY displaced by all the ligands studied is higher than 100%, thus inferring that naloxone (used to determine nonspecific binding) does not bind to all the sites labeled by [(3)H]MEGY. Therefore, we can deduct that some of the MEGY binding sites should not be considered classical opioid sites.
Collapse
Affiliation(s)
- V González-Nuñez
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Salamanca, Avda. Alfonso X El Sabio, s/n 37007 Salamanca, Spain
| | | | | | | | | | | |
Collapse
|
10
|
Bujdosó E, Jászberényi M, Farkas J, Tóth G, Wollemann M, Telegdy G. Behavioral and neuroendocrine actions of the Met-enkephalin-related peptide MERF. Horm Behav 2003; 43:302-11. [PMID: 12694640 DOI: 10.1016/s0018-506x(03)00004-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The effects and the mediation of the action of the proenkephalin derivative Met(5)-enkephalin-Arg(6)-Phe(7) (MERF) on the hypothalamo-pituitary-adrenal (HPA) system and open-field behavior were investigated in mice. Intracerebroventricular injection of the heptapeptide increased square crossing, rearing, and plasma corticosterone level. To characterize the receptors involved in these neuroendocrine processes, animals were pretreated either with the nonselective opioid antagonist naloxone or the kappa-antagonist nor-binaltorphimine (nor-BNI). Both antagonists dose-dependently attenuated the HPA activation elicited by MERF. Naloxone also blocked the behavioral responses, but nor-binaltorphimine did not elicit a significant inhibition. The dopamine antagonist haloperidol and a corticotropin-releasing hormone (CRH) antagonist were also preadministered to shed light on the transmission of the actions of MERF. Both the motor responses and the HPA activation were diminished by the preadministration of the CRH antagonist, while haloperidol attenuated only square crossing and rearing. To investigate the direct effect of MERF on the dopaminergic system, dopamine release of striatal slices was measured in a superfusion system. Neither the basal nor the electric impulse-evoked dopamine release was modified by MERF. The results suggest that opioid-mediation predominate in the neuroendocrine actions of MERF, and the effect of the heptapeptide on the HPA system seems to be mediated by kappa-receptors. In the behavioral responses evoked by MERF, both CRH release and the action of the dopaminergic neurons of the subcortical motor system might be involved. MERF also appears to activate the paraventricular CRH neurons, but dopaminergic transmission does not seem to play a significant role in its hypothalamic action.
Collapse
Affiliation(s)
- E Bujdosó
- Department of Pathophysiology, University of Szeged, Neurohumoral Research Group, Hungarian Academy of Sciences, Szeged, Hungary
| | | | | | | | | | | |
Collapse
|